Pipeline Review for Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) - H1 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Adrenoleukodystrophy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 3 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

Companies Mentioned

  • Applied Genetic Technologies Corp
  • bluebird bio Inc
  • MedDay SA
  • Minoryx Therapeutics sl
  • SOM Biotech SL
  • Viking Therapeutics Inc

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Overview
  4. Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type
  15. Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Companies Involved in Therapeutics Development
  16. Applied Genetic Technologies Corp
  17. bluebird bio Inc
  18. MedDay SA
  19. Minoryx Therapeutics sl
  20. SOM Biotech SL
  21. Viking Therapeutics Inc
  22. Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Drug Profiles
  23. biotin - Drug Profile
  24. Product Description
  25. Mechanism Of Action
  26. R&D Progress
  27. DRX-065 - Drug Profile
  28. Product Description
  29. Mechanism Of Action
  30. R&D Progress
  31. DUOC-01 - Drug Profile
  32. Product Description
  33. Mechanism Of Action
  34. R&D Progress
  35. elivaldogene tavalentivec - Drug Profile
  36. Product Description
  37. Mechanism Of Action
  38. R&D Progress
  39. Gene Therapy to Activate ABCD1 for Adrenoleukodystrophy - Drug Profile
  40. Product Description
  41. Mechanism Of Action
  42. R&D Progress
  43. MGTA-456 - Drug Profile
  44. Product Description
  45. Mechanism Of Action
  46. R&D Progress
  47. MIN-102 - Drug Profile
  48. Product Description
  49. Mechanism Of Action
  50. R&D Progress
  51. OP-101 - Drug Profile
  52. Product Description
  53. Mechanism Of Action
  54. R&D Progress
  55. pioglitazone hydrochloride - Drug Profile
  56. Product Description
  57. Mechanism Of Action
  58. R&D Progress
  59. sobetirome - Drug Profile
  60. Product Description
  61. Mechanism Of Action
  62. R&D Progress
  63. SOM-1201 - Drug Profile
  64. Product Description
  65. Mechanism Of Action
  66. R&D Progress
  67. Stem Cell Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile
  68. Product Description
  69. Mechanism Of Action
  70. R&D Progress
  71. temsirolimus - Drug Profile
  72. Product Description
  73. Mechanism Of Action
  74. R&D Progress
  75. VK-0214 - Drug Profile
  76. Product Description
  77. Mechanism Of Action
  78. R&D Progress
  79. VK-2809 - Drug Profile
  80. Product Description
  81. Mechanism Of Action
  82. R&D Progress
  83. Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) - Dormant Projects
  84. Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) - Product Development Milestones
  85. Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/nc6cmk/pipeline_review?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs